MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

ABSTRACT: PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.

SUBMITTER: Maifrede S 

PROVIDER: S-EPMC5728460 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature